Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997248 | 1.00 | RET (0.41) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL6599489 | 0.94 | FLT3 (0.39) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL6599490 | 0.94 | FLT3 (0.39) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4994729 | 0.93 | HRH1 (0.45) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4994734 | 0.93 | HRH1 (0.45) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4988138 | 0.90 | RET (0.51) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4988148 | 0.90 | RET (0.51) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4993441 | 0.90 | MAPT (0.44) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4993432 | 0.90 | MAPT (0.44) | RETPDGFRBERBB2ALDH1A1CRHBP | |
| SCHEMBL4990835 | 0.88 | PAK1 (0.39) | ALDH1A1CRHBPHTTCRHR2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9233070-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9056045-B2 | Intraocular biodegradable microspheres | ALLERGAN, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-8968766-B2 | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8642067-B2 | Methods and compositions for intraocular administration to treat ocular conditions | ALLERGEN, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20140031408-A1 | Biodegradable Intravitreal Tyrosine Kinase Implants | ALLERGAN, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8512738-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130210862-A1 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS | ALLERGAN, INC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8481069-B2 | Tyrosine kinase microspheres | ALLERGAN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8465778-B2 | Method of making tyrosine kinase microspheres | ALLERGAN, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-03-23 | — | — | US | disclosed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050228036-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2005-10-13 | — | — | US | disclosed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | disclosed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228036-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RET 133/4885PDGFRB 307/4885ERBB2 1/4885 |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RET 133/4885PDGFRB 307/4885ERBB2 1/4885 |
| US-20140031408-A1 | Biodegradable Intravitreal Tyrosine Kinase Implants | KDR, PTK2B, DSTYK | RET 11/4885PDGFRB 181/4885ERBB2 7/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RET 133/4885PDGFRB 307/4885ERBB2 1/4885 |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RET 133/4885PDGFRB 307/4885ERBB2 1/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | RET 11/4885PDGFRB 179/4885ERBB2 7/4885 |
| US-20130210862-A1 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS | DSTYK, PTK2B, PTK2 | RET 17/4885PDGFRB 209/4885ERBB2 4/4885 |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RET 133/4885PDGFRB 307/4885ERBB2 1/4885 |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RET 133/4885PDGFRB 307/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.